Founded with the mission to revolutionize cancer treatment, Shasqi leverages click chemistry to deliver targeted therapies directly to tumors. Utilizing its proprietary CAPAC™ platform, Shasqi's technology localizes a click chemistry reagent in the tumor area, which activates a systemically infused protodrug upon interaction. This innovative approach ensures powerful localized therapy while minimizing systemic toxicity. Shasqi focuses on developing advanced cancer therapeutics, aiming to significantly improve patient outcomes.
Notable figures affiliated with Shasqi include experts in oncology and medicinal chemistry, who contribute to the company's pioneering efforts. Key investors support the company's groundbreaking research and development. Among its achievements, Shasqi has presented promising Phase 2a results of its SQ3370 therapeutic at major conferences like ASCO and AACR. The company's impact lies in its potential to transform cancer treatment paradigms, offering more effective and safer options for patients worldwide.
